[go: up one dir, main page]

EP4466002A1 - Composition pour application topique contenant des solubilisats de substances actives lipophiles - Google Patents

Composition pour application topique contenant des solubilisats de substances actives lipophiles

Info

Publication number
EP4466002A1
EP4466002A1 EP23701635.7A EP23701635A EP4466002A1 EP 4466002 A1 EP4466002 A1 EP 4466002A1 EP 23701635 A EP23701635 A EP 23701635A EP 4466002 A1 EP4466002 A1 EP 4466002A1
Authority
EP
European Patent Office
Prior art keywords
cbd
composition
mask
solubilisate
vitamin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23701635.7A
Other languages
German (de)
English (en)
Inventor
Marcus Furch
Anastasia LOSA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Solmic Biotech GmbH
Original Assignee
Solmic Biotech GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE202022000150.9U external-priority patent/DE202022000150U1/de
Priority claimed from EP22173218.3A external-priority patent/EP4275694A1/fr
Application filed by Solmic Biotech GmbH filed Critical Solmic Biotech GmbH
Publication of EP4466002A1 publication Critical patent/EP4466002A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3486—Humulus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/577—Malvaceae (Mallow family)

Definitions

  • the invention relates to products for topical application containing micellized extracts or micellized lipophilic active ingredients.
  • EP 1 768 497 B1 therefore describes the production of solubilizates of essential oils in order to be able to homogeneously introduce substances which are insoluble or sparingly soluble in water into end products.
  • EP 3 820 528 A1 describes solubilisates with curcumin and at least one cannabinoid as an additional active substance in order to produce capsules from them that act as food supplements or medicinal products.
  • WO 2021/037656 AA11 describes folic acid solubilisates which are used in food supplements and in waste water treatment in septic tanks.
  • WO 2021/175763 A1 describes topical compositions containing cannabidiol encapsulated in niosomes.
  • the niosomes consist of a hydrophobic bilayer and a hydrophilic core, i.e. fat-soluble substances are trapped between the bilayers while water-soluble substances can be trapped inside the core.
  • WO 2021/030789 A1 relates to nano-encapsulated cannabidiol, which is used alone or together with naltrexone as a therapeutic agent in a number of diseases, such as pain conditions, Parkinson's disease, Alzheimer's disease, multiple sclerosis, Crohn's disease and inflammation.
  • the object of the present invention is to provide products for topical application in which care or healing active ingredients for the skin are prepared in such a way that they are readily absorbed by the skin and lead to an improvement in the skin's appearance. Furthermore, the products should be characterized by good stability and durability
  • the invention thus relates to a product or a composition for topical application which contains solubilisates of lipophilic active substances as defined in claim 1.
  • solubilizates of the lipophilic active ingredients as defined in claim 1 are used to prepare products or compositions for topical application.
  • the products contain solubilized active ingredients which, compared to the pure isolates of the active ingredients, can be better processed into the product and contribute to improved stability there.
  • solubilisates are water-soluble micelles that encapsulate lipophilic substances. Solubilisates are manufactured with the aim of enclosing lipophilic or non- or poorly water-soluble substances in such a way that they become water-soluble. A combination of emulsifier(s), fat-soluble active ingredients and auxiliary substances forms stable, transparent and water-soluble solubilisates.
  • Preferred emulsifiers are polysorbates, poloxamer (Lutrol), gum arabic, sucrose stearate, DermofeelG 10 LW (70) MB, pasty Dermofeel® G 10 L, PEG-40 hydrogenated castor oil (hydrogenated castor oil), lecithin, phospholipon, or D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS; other designations: Vitamin E TPGS, To cofersolan (INN)) used.
  • poloxamers are suitable emulsifiers.
  • Poloxamers are synthetic block copolymers of ethylene oxide and propylene oxide.
  • Poloxamers are amphiphilic.
  • TPGS is another amphiphilic emulsifier that has a hydrophilic and a lipophilic Has molecular part.
  • a polyethylene glycol moiety represents the polar head and the tocopherol succinate represents the lipophilic tail.
  • This amphiphilic property leads to self-association (micelle formation) of TPGS in water.
  • fat-soluble components are included in the interior of the micelle (lipophilic part) and dissolved in water through the water-soluble surface of the micelle.
  • Possible auxiliaries to improve the solubility of the poorly water-soluble substances are, for example, ethanol (96%), polysorbate, glycerine (anhydrous).
  • EP 3 675 825 EP 18 738 297)
  • EP 3 675 824 EP 18 737 274.
  • the active ingredients which are stably enclosed in micelles, are protected from thermal and light influences and/or chemical instability (e.g. oxidation).
  • the micelles are characterized by the fact that a hydrophobic core, in which the fat-soluble substances are enclosed, is surrounded by a hydrophilic emulsifier layer.
  • the solubilisate is used as a single raw material. This has the advantage that it can be installed directly in the water phase or can completely replace the water phase. This means that not only O/W (oil in water) but also W/O (water in oil) and purely aqueous products can be produced without the addition of fat/oil or emulsifiers.
  • the water-soluble micelles are evenly distributed in the aqueous solution. This achieves the homogeneity of the active ingredient in the product.
  • hydrophobic active ingredients extracts, lipophilic vitamins, etc. packed in the micelle are protected from external influences in the micelle. This ensures improved stability of the active ingredient in the product.
  • lipophilic plant extracts As active ingredients in the above-mentioned products for topical application, lipophilic plant extracts, plant extracts, phytotherapeutics, algae, resins, vitamins, enzymes, proteins, functional active substances and/or coenzymes as well as mixtures and combinations thereof can be considered. All of the active ingredients mentioned have a positive effect on the skin in common, which includes both cosmetic use for the care and cleansing of all skin types, in particular to achieve an anti-aging effect, and therapeutic applications for skin diseases such as acne, erysipelas, urticaria, herpes, neurodermatitis, burns or psoriasis.
  • skin diseases such as acne, erysipelas, urticaria, herpes, neurodermatitis, burns or psoriasis.
  • Examples of possible plant extracts or plant extracts or phytotherapeutics are evening primrose (Oenothera biennis), balloon vine (Cardiospermum halicacabum), wild pansy (Viola tricolor), horsetail (Equisetum arvense), real chamomile (Matricaria recutita), magic shrub (Hamamelis virginiana), mahonia (Mahonia aquifolium), birch (Betula pendula), ylang Ylang, Siberian Ginseng (Eleutherocokk), Shea Butter (Shea Butter), Cannabis Plant (Cannabinoids), Turmeric (Curcuma langa), Common Lavender (Lavandula angustifolia), St.
  • the active ingredient is a cannabinoid such as tetrahydrocannabiol (THC), cannabidiol (CBD), cannabichromene (CBC), cannabichromevarin (CBCV), cannabigerol (CBG), cannabigerovarin (CBGV), cannabinol (CBN) or cannabicyclol.
  • cannabinoid such as tetrahydrocannabiol (THC), cannabidiol (CBD), cannabichromene (CBC), cannabichromevarin (CBCV), cannabigerol (CBG), cannabigerovarin (CBGV), cannabinol (CBN) or cannabicyclol.
  • Examples of possible algae are brown algae, red algae, green algae or blue-green algae.
  • vitamins examples include vitamin E, vitamin A, pro-vitamin A (beta-carotene), vitamin C, vitamin B3 (niacin), panthenol, pro-vitamin B5 and vitamin B7 (biotin).
  • enzymes, proteins and coenzymes are lipases, cellulases, amylases, proteases, collagen, acetyl-hexapeptide-8, pentapeptide-18 or ubiquinone-10 (Q10),
  • Examples of possible resins are frankincense, propolis or myrrh.
  • Examples of other functional active ingredients are fruit acids (e.g. glycolic acid, lactic acid, malic acid, citric acid, tartaric acid), resveratrol, pterostilbene, astaxanthin or substances that can interact with the functional pathways of hypoxia-induced factor (HIF), mTor, p53, GDNF, GLUT1.
  • fruit acids e.g. glycolic acid, lactic acid, malic acid, citric acid, tartaric acid
  • resveratrol e.g. glycolic acid, lactic acid, malic acid, citric acid, tartaric acid
  • resveratrol e.g. resveratrol, pterostilbene, astaxanthin
  • astaxanthin e.g. glycolic acid, lactic acid, malic acid, citric acid, tartaric acid
  • resveratrol e.g. glycolic acid, lactic
  • micellized CBD canbidiol
  • One or more other (water-soluble) substances that have a positive effect on the skin e.g. hyaluronic acid, aloe vera, centella extract, green tea extract, lactic acid, urea or amino acids can be added to the solubilisate or the product for topical application.
  • the (water-soluble) substances can be applied directly to the mask.
  • cosmetic or pharmaceutical auxiliaries such as stabilizers, emulsifiers, preservatives, thickeners and/or binders can also be present.
  • emulsifier So that oil and water do not repel each other, all emulsions require an emulsifier or solubilizer to ensure their stability.
  • the emulsifier is located at the interface between the two liquids and has both a polar and a non-polar part of the molecule.
  • the polar ends of the emulsifier molecules attach themselves to the water, the non-polar ends to the oil molecules.
  • suitable emulsifiers are Laureth 4, Ceteareth -15, PEG-8, sucrose stearate (E 473), methyl glucose sequistearate or glyceryl stearate.
  • Stabilizers are often added to the emulsifiers. These cover the emulsified droplets with a protective film and ensure strong cohesion.
  • Stabilizers are, for example, antioxidant vitamins, starch, dextrins, pectins or proteins.
  • Stabilizers preferred according to the invention are vitamin C or vitamin E, preferably in an amount of 0.2-1.8% by weight, very preferably 0.5-1.0% by weight.
  • Thickeners in cosmetic products ensure that the products always have an optimal consistency and increase viscosity. For example, they make lotions more viscous and creamy, which makes them easier to apply and makes the skin feel soft.
  • These can be synthetic thickeners such as liquid micro-plastic particles or natural thickeners such as cellulose (E 460), xanthan gum (E 415), algin (E 400 - E 405), gellangum (E 418), pectin (E 440) or carrageenan (E 407).
  • the natural thickeners although more expensive, are clearly preferred as microplastics are a clear environmental concern.
  • Preservatives protect cosmetic products from microbial spoilage and thus make an important contribution to consumer health. Products containing water are particularly at risk because microorganisms can easily settle and multiply. Preservatives that are often used are parabens, alcohols (e.g. ethyl alcohol) or halogenated organic substances (e.g. benzoisothiazolinone, methylisothiazolinone, dichlorobenzyl alcohol, chlorhexidine).
  • alcohols e.g. ethyl alcohol
  • halogenated organic substances e.g. benzoisothiazolinone, methylisothiazolinone, dichlorobenzyl alcohol, chlorhexidine
  • Binders as ingredients in cosmetics ensure the desired cohesion of the products. They prevent solids and liquid components from separating. The amounts used are usually less than 2% of the total mass. Hydrophilic colloids (e.g. alginates) as well as carboxymethyl cellulose, hydroxyethyl cellulose or xanthan are frequently used.
  • Hydrophilic colloids e.g. alginates
  • carboxymethyl cellulose, hydroxyethyl cellulose or xanthan are frequently used.
  • the active substance solubilisates when using the active substance solubilisates, a higher stability of the product for topical application can be achieved compared to the isolates of the active substances.
  • the stability achieved by the active ingredient solubilisates can be further increased by adding stabilizers.
  • the solubilisates are clearly superior to the isolates, since the solubilisates already contribute to the stability of the product contribute without the need for additional stabilizers.
  • vitamin E is added in a higher concentration (eg 1%), the solubilisate is clearly more stable than the isolate. This effect can still be observed at least in creams with a higher fat content with 1% vitamin E plus 1% vitamin C.
  • solubilisates Due to the water-soluble property of the solubilisates, they are predestined for use in cosmetic products where no fats or oils are desired, such as shampoos or masks.
  • the micelle protection protects the active ingredient in the inner core from exposure to light, which benefits product stability in daily use.
  • the product to be applied to the skin is a (face) mask for medical or cosmetic purposes, which contains micellar extracts or micellar lipophilic active ingredients.
  • a ready-to-use mask for cosmetic or medical purposes in which active ingredients for the care or healing treatment of the skin are prepared in such a way that they are well absorbed by the skin and lead to an improvement in the skin's appearance.
  • the mask In order to allow visual perception and unimpeded breathing during treatment, the mask, if it covers the entire face, has perforated openings for the eyes and nose. This increases the well-being of the user and allows individual adjustment to his needs. But it is also possible that the mask only covers parts of the face or neck. It is also possible that it extends to the Vietnameselleté or covers other parts of the body.
  • the mask is made of a flexible material. This can be cellulosic material, cotton-containing material or silk-containing material, as well as any combinations and mixtures thereof.
  • Biocellulose is preferred, most preferably a material consisting of 90-98% water and 2-10% cellulose. In a preferred embodiment, masks consisting of 96% water and 4% cellulose are used.
  • biocellulose is understood to mean a smooth, roughened or knobbed, flat fabric material that is used to manufacture the face mask.
  • the face mask can be made of cellulose or cellulose fleece, in one or more layers.
  • the bio-cellulose mask is made from fermented bacteria. It is 100% compostable and due to its composition it adheres well to the skin.
  • Other preferred features of the biocellulose mask are:
  • the thickness of the layer(s) is flexible and depends on the liquid absorption of the face mask required for the respective application.
  • the cut of the mask may vary.
  • the mask can cover the whole face, parts of the face, neck, Vietnameselleté or other parts of the body.
  • mask and “face mask” are used interchangeably, and the term “face” is not intended to be limited to the face alone, but includes the head and neck. It acts as a carrier for active substances that can penetrate the skin.
  • the masks according to the invention are preferably packaged sterile and individually.
  • the mask (particularly biocellulose mask) lies on a moistened non-woven cloth and is covered with a perforated white plastic film and allows the mask to be folded in the packaging and protects it from drying out.
  • the packaging is preferably an aluminum foil which can be printed, for example by means of CMYK printing.
  • the face mask preferably has eye, nose and possibly mouth perforations. There may be optional passages in the cheek area to accommodate the ears of the mask wearer. One differentiates on the face a forehead and chin area as well as a central eye, nose, mouth and cheek area. Corresponding areas of the face mask are assigned to these parts. On the side next to the central face part of the face mask, the optional passages for receiving the ears can be arranged, which enclose the ears and fix the face mask securely. As a result, the face mask cannot unintentionally slip off the face during treatment.
  • At least one recess is also provided for the nose, which is formed by a trapezoidal opening which, in the direction of the axis of symmetry of the face surface, can have an incision or cut in the face mask up to the level of the eye area, in order to enable adaptation to different nose shapes.
  • the part of the mask enclosed by the perforation is placed on the nose, thus forming a passage for the nose.
  • the above-mentioned active ingredients stably encapsulated in micelles are protected from thermal, light influences and/or chemical instability (e.g. oxidation).
  • the masks are mostly water, they can be loaded with micelles. The mask releases its moisture to the skin and thus also the active ingredients. Experiments have shown that the masks absorb at least 20%, preferably at least 50%, of the solubilisate used in production.
  • John's wort Hypericum perforatum
  • Irish s moss Choondrus crispus
  • hops Humulus lupulus
  • green tea Camellia sinensis L.
  • centella Centella asiatica
  • mallow Malva sylvestris
  • meadowsweet Fulipendula ulmaria
  • marigold Calendula officinalis L.
  • red clover Trifolium pratense
  • vitamins preferably being vitamin E, vitamin A, pro-vitamin A (beta-carotene), vitamin C, vitamin B 3 (niacin) and/or vitamin B7 (biotin),
  • enzymes, proteins or coenzymes are preferably lipases, cellulases, amylases, proteases, collagen, acetyl hexapeptide-8, pentapeptide-18 and/or ubiquinone-10 (Q10),
  • the functional active ingredients are astaxanthin, resveratrol, pterostilbene, fruit acids or substances that can interact with the functional pathways of hypoxia-induced factor (HIF), mTor, p53, GDNF, GLUT1,
  • HIF hypoxia-induced factor
  • the solubilisates being a combination of emulsifier(s), fat-soluble active ingredients and excipients, the emulsifier(s) preferably being selected from polysorbates, lutrol and/or D-alpha-tocopheryl polyethylene glycol 1000 succinate and the excipients preferably being ethanol, polysorbate and/or glycerol.
  • the mask is preferably made of biocellulose.
  • the mask can be used for cosmetic purposes for the care and cleansing of any skin type, with an anti-aging effect on the skin preferably being achieved.
  • the mask can also be used for therapeutic use in skin diseases, the skin disease preferably being acne, herpes, neurodermatitis, urticaria, erysipelas, burns or psoriasis.
  • Fig. 1 CBD in acetone itril/water in daylight and RT
  • CBD in acetonitrile/water reduces to approximately 3.7% of the initial concentration over a period of 281 days
  • Fig. 2 CBD in acetonitrile/water in the dark and 4°C
  • CBD in acetonitrile/water is reduced to 81.9% of the initial concentration over a period of 281 days
  • Fig. 3 CBD poloxamer in daylight and RT
  • CBD in the solubilisate is reduced to 50.4% of the initial concentration over a period of 275 days
  • Fig. 4 CBD poloxamer in the dark and 4 °C
  • the CBD concentration in the solubilisate remains stable over a period of 275 days
  • Fig. 5 Face mask made from biocellulose on a fabric
  • Fig. 6 Face mask, where the existing perforations for eyes,
  • solubilisate is added to the water phase.
  • the pre-dissolved gel binders are added to the water phase and stirred until the gel thickens.
  • Other active ingredients and preservatives are added.
  • the gel which consists of 80% aqueous phase and thus promotes the growth of germs, was subjected to the germ load test
  • 1 g sample is usually diluted 1:10 with Eugon LT SUP buffer. To test for sufficient preservation, the sample is inoculated with 1% of the respective germ suspension. The inoculated samples are stored at 22.5 ⁇ 2.5 °C until the respective re-isolation time. After T7, T14 and T28, the number of each microorganism is determined using the surface plating method. When performing a recovery, each 1 g sample is inoculated individually with the corresponding germ suspension in a ratio of 1:10. In the control batch, inoculation takes place without a sample. Result:
  • T7, T14, T28 sampling times in days
  • test for antimicrobial protection test for sufficient preservation
  • the product meets criteria A and B according to Appendix B of DIN EN ISO 11930.
  • propolis solubilisate which was produced from the ethanolic propolis extract, was placed in 50 ml brown glass bottles
  • Example 3 No germs were detected in any of the samples examined, either at room temperature or at 40 °C. Beyond the six months, microbiological tests were also carried out after 12 months. Due to the changed viscosity, the samples had to be diluted 1:10, so the detection limit was 10 and no germs could be detected in the solubilisate even after this time.
  • Example 3
  • samples of propolis solubilisate were stored at room temperature and 40 °C. Samples were taken at the following times: Day 0, 30, 90 and 270. The following parameters were determined. colour, turbidity, pH value, density and sediment. Since propolis is naturally darker in color, the samples were diluted 1:10 with water to detect turbidity and determine the pH value.
  • Cannabinoids are particularly sensitive to light, which causes the formation of specific oxidation products. Therefore, an HPLC experiment was performed to investigate the difference in the stability of CBD in aqueous-organic solution (acetonitrile/water) compared to a 1 wt% CBD formulation with poloxamer. The samples were exposed to the natural daylight cycle for up to 281 days and measured at regular intervals. As a negative control, identically formulated samples were stored in the dark and at 4°C.
  • cannabidiol purity 97%) were weighed into a 100 ml volumetric flask and filled up with acetonitrile/H2O (60/40).
  • 1% cannabidiol solubilisate is produced with poloxamer, corresponds to 10 mg/ml cannabidiol
  • the poloxamer formulation shows a higher stability of CBD compared to the aqueous-organic (ACN/H2O) solution. After more than 275 days of exposure to the natural daylight cycle at room temperature, the concentration of CBD in the aqueous-organic solution has decreased to 3.7% of the starting level (the darkness control at 80%). In comparison, the CBD concentration in the formulation with poloxamer is reduced to 50.4% (the dark control did not show any reduction of CBD).
  • the day cream consists of more than 50% aqueous content, 21% fat phase, which already includes the emulsifier, 0.1% cannabidiol isolate or 1% cannabidiol solubilizate and other active ingredients.
  • the difference in production is the addition of the respective cannabidiols. While the CBD isolate is melted in the fat phase, the CBD solubilisate is dissolved in the water phase.
  • CBD solubilisate 1% cannabidiol in the solubilisate results in a final concentration in the product of 0.01% cannabidiol.
  • the samples produced were stored in a climatic cabinet at room temperature and 40.degree.
  • the measurement shows that without the addition of stabilizers (vitamin E and vitamin C), the CBD in the micelle (COS013-AL-012) has a slightly higher stability after 90 days than the similar day cream with CBD isolate (COS013-AL-008).
  • CBD serum 5% fat content
  • Rose hydrolate water, propylene, jojoba oil, lecithin, betaine, hydroxyethyl cellulose, myristyl myristate, potassium sorbate, xanthan gum, CBD isolate or CBD solubilizate 1% and/or vitamin C, vitamin E
  • the serum consists of 70% aqueous content, 5% fat phase, emulsifier, 0.1% cannabidiol isolate or 1% cannabidiol solubilisate and other active ingredients.
  • the fat phase After the fat phase has melted, it is emulsified with the water phase and the other active ingredients are incorporated.
  • the difference in production is the addition of the respective cannabidiols. While the CBD isolate is melted in the fat phase, the CBD solubilisate is dissolved in the water phase.
  • CBD solubilisate 1% cannabidiol in the solubilisate results in a final concentration in the product of 0.01% cannabidiol.
  • the samples produced were stored in a climatic cabinet at room temperature and 40.degree.
  • the cut mask is placed in an airtight package and loaded with the essence containing solubilized ubiquinone at the filling line.
  • the system releases a certain amount of 15-45 g of essence into the finished package.
  • the essence is evenly distributed by repeatedly pressing the packaging sideways so that the mask is completely wetted with the essence.
  • the packaging is then sealed. After storage for 3-7 days, the mask is saturated with the essence.
  • the mask immersed in 3% essence solution was cut into approx. 1 g pieces and filled up in a tube with approx. 4 g tetrahydrofuran (THF) and inserted for at least 4 hours. During the extraction time, the sample material was vortexed in the tube. The total weight of the mask sample and that of the solvent were added up and documented.
  • THF tetrahydrofuran
  • the content in the extracted solution could be determined using the 6-point calibration curve between 1-100 pg/ml.
  • the quality control samples which must show a predefined value (3 pg/ml, 50 pg/ml, 80 pg/ml) during a run, acted as a control. After measuring the extraction, around 50% of the raw material used was recovered. The essence was measured. The determined and validated value was taken as the initial value.
  • the mask soaked in 3% essence solution was cut into approx. 1 g pieces and filled with approx. 4 g water (H2O) in a small tube and soaked for at least 4 hours. During the extraction time, the sample material was vortexed in the tube. The total weight of the mask sample and that of the solvent were added up and documented.
  • the mask immersed in 3% essence solution was cut into approx. 1 g pieces and filled up in a tube with approx. 4 g tetrahydrofuran (THF) and inserted for at least 4 hours. During the extraction time, the sample material was vortexed in the tube. The total weight of the mask sample and that of the solvent were added up and documented.
  • THF tetrahydrofuran
  • the mask immersed in 3% essence solution was cut into approx. 1 g pieces and filled up in a tube with approx. 4 g water/acetonitrile (90/10 v/v) and inserted for at least 4 hours. During the extraction time, the sample material was vortexed in the tube. The total weight of the mask sample and that of the solvent were added up and documented.
  • the content in the extracted solution could be determined.
  • the essence and the solubilisate used were also measured. After measuring about 66% of the raw material used was recovered during the extraction. The determined and validated value was taken as the initial value.
  • the measurement data of the solubilisates in the masks are as follows: The measurement data show that the concentration of raw materials used must be taken into account, since diffusion takes place as a result of material equalization.
  • the solubilisates in the masks remain stable and the liquid surrounding the masks (essence) with the solubilisates also remains stable. Assuming storage at 40 °C, the stability of the solubilisates in the masks is guaranteed for at least 12 months.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition pour application topique à des fins médicales ou cosmétiques, qui contient des extraits micellisés ou des substances actives lipophiles micellIisées, en particulier une composition qui contient un ou plusieurs solubilisats de substances actives lipophiles sur la base d'extraits de plantes, d'extraits végétaux, de parties végétales, d'agents phytothérapeutiques, de résines, de vitamines, d'enzymes, de protéines, d'algues, de substances actives fonctionnelles et/ou de coenzymes, et des mélanges et combinaisons de ceux-ci.
EP23701635.7A 2022-01-20 2023-01-18 Composition pour application topique contenant des solubilisats de substances actives lipophiles Pending EP4466002A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE202022000150.9U DE202022000150U1 (de) 2022-01-20 2022-01-20 Maske für medizinische oder kosmetische Zwecke mit mizellierten Extrakten
EP22173218.3A EP4275694A1 (fr) 2022-05-13 2022-05-13 Utilisation de solubilisats dans des articles destinés à l'application topique
PCT/EP2023/051097 WO2023139105A1 (fr) 2022-01-20 2023-01-18 Composition pour application topique contenant des solubilisats de substances actives lipophiles

Publications (1)

Publication Number Publication Date
EP4466002A1 true EP4466002A1 (fr) 2024-11-27

Family

ID=85036741

Family Applications (2)

Application Number Title Priority Date Filing Date
EP23701634.0A Pending EP4466001A1 (fr) 2022-01-20 2023-01-18 Masque à usage médical ou cosmétique contenant des extraits micellisés
EP23701635.7A Pending EP4466002A1 (fr) 2022-01-20 2023-01-18 Composition pour application topique contenant des solubilisats de substances actives lipophiles

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP23701634.0A Pending EP4466001A1 (fr) 2022-01-20 2023-01-18 Masque à usage médical ou cosmétique contenant des extraits micellisés

Country Status (3)

Country Link
EP (2) EP4466001A1 (fr)
CN (1) CN119278046A (fr)
WO (2) WO2023139105A1 (fr)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57166514U (fr) 1981-04-16 1982-10-20
DE19930838A1 (de) 1999-07-03 2001-01-11 Evelin Gutmann Gesichtsmaske
DE10002350A1 (de) 2000-01-20 2001-08-09 Monika Dabs Gesichtsmaske
ATE439049T1 (de) 2004-07-22 2009-08-15 Aquanova Ag Solubilisate von ätherischen ölen und anderen stoffen
US20120211022A1 (en) 2011-02-17 2012-08-23 Koji Nakamura Cosmetic face mask
EP3424494A1 (fr) 2017-07-07 2019-01-09 SolMic Research GmbH Compositions de cannabinoïde stables
EP3424493A1 (fr) 2017-07-07 2019-01-09 SolMic Research GmbH Compositions de cannabinoïde stables
CN110575448A (zh) * 2018-06-08 2019-12-17 云南汉素生物科技有限公司 大麻二酚组合物及其用途
JP7254898B2 (ja) 2018-07-11 2023-04-10 アクアノヴァ アクチエンゲゼルシャフト クルクミンと、更なる活性物質としての少なくとも１つのカンナビノイドとを含む可溶化物
EP3934621B1 (fr) * 2019-03-07 2025-06-25 Hug Research Labs Srl Préparation à usage topique pour traitements dermatologiques
EP4013326A1 (fr) * 2019-08-13 2022-06-22 Boston Scientific Scimed, Inc. Dispositifs d'ablation expansibles
WO2021030789A1 (fr) 2019-08-15 2021-02-18 Castor Trevor P Cannabidiol nanoencapsulé
DE202019104734U1 (de) 2019-08-29 2020-12-01 Aquanova Ag Folsäure-Solubilisat
IT202000004450A1 (it) 2020-03-03 2021-09-03 Curaleaf International Ltd Composizione topica comprendente cannabidiolo
DE202022000150U1 (de) * 2022-01-20 2022-07-07 Solmic Bio Tech Gmbh Maske für medizinische oder kosmetische Zwecke mit mizellierten Extrakten

Also Published As

Publication number Publication date
EP4466001A1 (fr) 2024-11-27
WO2023139101A1 (fr) 2023-07-27
CN119278046A (zh) 2025-01-07
WO2023139105A1 (fr) 2023-07-27

Similar Documents

Publication Publication Date Title
EP2320754B1 (fr) Microémulsion
DE60130466T2 (de) Antipruritische zusammensetzungen und die wundheilung fördernde zusammensetzungen
CN105640796B (zh) 一种具有高保湿性能的组合物及其在婴儿膏霜中的应用
EP1140006B1 (fr) Agents pour proteger la peau, contenant un melange de fragments produit par hydrolyse a partir d'acide hyaluronique
EP2494968A1 (fr) Composition, notamment pommade dermatologique avec de l'huile des fruits d'Olea Europaea et de l'argent
CN112972310A (zh) 一种具有抑菌修复作用的组合物及其制备方法
CH697417B1 (de) Mittel zur Behandlung der Hautalterung enthaltend Paeoniflorin.
CH699835B1 (de) Wasserdispergierbarer oder wasserlöslicher Polymerfilm als Träger von dermatologischen und kosmetischen Wirkstoffen.
DE202022000150U1 (de) Maske für medizinische oder kosmetische Zwecke mit mizellierten Extrakten
DE69803054T2 (de) Zusammensetzung auf der basis von pflanzenextrakten und ätherischen ölen, verwendbar in therapeutika, kosmetika und diätnahrung
EP4466002A1 (fr) Composition pour application topique contenant des solubilisats de substances actives lipophiles
EP1537789B1 (fr) Composition pour application orale ou cosmétique
CN108113924A (zh) 一种复合植物舒敏剂及其制备方法与应用
EP2386309B1 (fr) Bulbine frutescens gel
DE4433666A1 (de) Mittel zur Behandlung oder Pflege gereizter oder entzündeter Haut enthaltend einen Extrakt aus getrockneten oder frischen Spitzwegerichkraut (Plantago lanceolata. L.) in einer Grundlage, die die Anwendung auf der Haut als Stift, Roller oder Creme ermöglicht
EP4275694A1 (fr) Utilisation de solubilisats dans des articles destinés à l'application topique
EP2399648B1 (fr) Composition cosmétique et son utilisation
KR20220167685A (ko) 천연방부제를 함유하는 화장료 조성물
DE2749960B2 (de) Verwendung von Benzylalkohol zur Herstellung reaktivierender kosmetischer Präparate
EP1566170A1 (fr) Produit pour le soin de la peau contenant acide ursolique et un extrait de gingko
EP4051217B1 (fr) Composition cosmétique contenant un extrait d'opuntia ficus indica
DE69600038T2 (de) Mittel in Form eines in Wasser selbstemulgierenden Pulver
EP2008638A1 (fr) Oxygène dans des préparations cosmétiques ou dermatologiques
EP4631497A1 (fr) Composition liposomale pour administration topique
DE202024106904U1 (de) Hautverträgliches, pflegendes und schützendes Mittel zum Auftragen auf die Haut

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240816

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)